Mid-Life Crisis? Venture Capital Acts Its Age

Published July 21, 2010

Mid-life Crisis? Venture Capital Acts Its Age
The venture capital community is showing signs of middle age — moving more slowly and cautiously than before, and hitting fewer home runs than it did in younger, leaner days. As a result, experts say, the sector is having trouble producing the robust performance long associated with it. This means investors need to look at venture capital, and its impact on their portfolios, in a new way.
Read more on Knowledge at Wharton

Shionogi-ViiV Healthcare to advance ‘572 inhibitor into Phase III clinical trials
Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 (‘572) into Phase III clinical trials. ‘572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.
Read more on News-Medical-Net